An Observational Study of Chinese Multiple Myeloma Patients Treated With Velcade

Treatment sequence or the line of therapy will be considered on Velcade utilization.

Dosage of Velcade will be considered on Velcade utilization. The unit of dosage will be milligram per square meter body surface area.

Duration of Velcade therapy will be measured on Velcade utilization. The unit of duration will be number of days or the length of the course of therapy.

Diagnosis of patients will be considered on Velcade utilization.

Complete response (CR), near complete response (complete response with positive immunofixation; nCR), partial response (PR), minimal response (MR), stable disease (SD), progressive disease (PD), or relapse from CR (RCR); the methods and criteria used to evaluate the responses will be chosen by the physician and recorded.

Time to response is calculated from the start date of the cycle of Velcade therapy.

Duration of response is calculated from the date on which response is documented until PD, RCR, death, or study termination occurs.

Time to progression is calculated from the date on which response is documented until PD or RCR occurs.

Survival status is calculated from the start of Velcade therapy until death; to be monitored, to the extent possible, beyond the end of Velcade therapy, up to the end of the study period.

Safety criteria will be considered for new skeletal events (fractures, radiotherapy of bone, operation on the bone, spinal cord compression), infection and haematological toxicity (with greater than or equal to grade 3 using WHO Common Toxicity Criteria [WHO CTC]), and any neurotoxic events by WHO CTC.

Emergency room visits will be considered as a measure of health care resource utilization associated with Velcade therapy.

Inpatient hospital stays and the reasons for hospitalization will be considered as a measure of health care resource utilization associated with Velcade therapy.

Days for each hospital stay will be considered as a measure of health care resource utilization associated with Velcade therapy.

Therapeutic therapies (eg: surgery) will be considered as a measure of health care resource utilization associated with Velcade therapy.

Concomitant medications will be considered as a measure of health care resource utilization associated with Velcade therapy. Concomitant medications include over-the-counter as well as prescription medications, start and stop dates, dosages, and indication. The compliance of concomitant medications will be evaluated by the percentage of patient reported dose over prescribed dose.

Multiple myeloma patients who receive two or more prior treatments and demonstrate disease progression on the most recent treatment will be indicated for Velcade therapy.

Sociodemographics of patients will be assessed, at the initiation of Velcade therapy, such as: gender, date of birth, height, weight, highest degree, and career information.

Chronic concomitant disease will be assessed at the initiation of Velcade therapy.

Treatment history will be assessed at the initiation of Velcade therapy. Treatment history includes: confirmation date of diagnosis of multiple myeloma patients or other patients receiving Velcade therapy; names of diseases for patient receiving Velcade therapy; prior treatments for multiple myeloma; outcomes of prior treatments for multiple myeloma.